Medications Used Under Heavy Sedation or General Anesthesia for Opioid Use Disorder
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 2.303 alerts
Get alerted when Policy MP 2.303 changes without checking for updates manually.
Monitor payer policy activity
This policy addresses use of opioid antagonist medications administered under heavy sedation or general anesthesia (ultra-rapid/anaesthesia-assisted withdrawal) for treatment of opioid use disorder and applies to Capital Blue Cross products where the medical policy is in effect.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Determinations
Not medically necessary / Investigational
Not covered when considered investigational
Evidence includes randomized and nonrandomized trials with limited data and safety concerns.
The presence of this medical policy does not by itself indicate that a service is a covered benefit under a member's health plan. Benefit determinations are governed by the member's specific health benefit plan language, which defines covered services, exclusions, limits, and preauthorization requirements. Providers and members should consult the member's health benefit plan or contact Capital Blue Cross for plan-specific coverage information.
Excerpts of the policy included here document editorial, coding review, consensus, and retirement history (for example, periodic consensus reviews and an entry noting a retirement review on 12/26/2024). These sections do not themselves state explicit criteria that establish coverage or exclusion of services; they reflect the policy’s revision and review history.
Ultra-rapid withdrawal (use of opioid antagonists administered under heavy sedation or general anesthesia) for treatment of opioid use disorder is considered investigational by this policy due to insufficient evidence of improved health outcomes and documented significant adverse events; therefore the intervention is not supported as a covered, standard treatment option.
The provided text excerpts do not contain a standalone phrase explicitly stating 'not medically necessary' for specific scenarios; the policy instead describes an overall investigational stance and documents editorial and review history.
Coding and Billing
| No specific CPT codes | The policy states that no specific CPT codes are listed. |
Provider Responsibilities and Authorization Notes
Benefit determination and coding note
Coverage for medications used under heavy sedation or general anesthesia for opioid use disorder is determined by the member's health benefit plan; preauthorization requirements depend on that plan. The policy does not list any specific CPT procedure codes.
- Benefit determinations are governed by the member's health benefit plan and may require preauthorization per plan terms.
- Policy coding section explicitly states: "*No specific CPT codes*".
Prior authorization not specified in these excerpts
The provided excerpts do not state any explicit prior authorization requirements for anesthesia-assisted or ultra‑rapid withdrawal procedures; check the member's benefit plan for any plan-specific preauthorization rules.
- The medical policy does not itself establish preauthorization criteria; the member's health benefit plan controls preauthorization.
Standard withdrawal options (non‑anesthesia)
Standard, non‑anesthesia withdrawal management options are described as established alternatives to ultra‑rapid techniques and may be used instead of anesthesia‑assisted antagonist procedures.
- Tapering doses of methadone or buprenorphine (including buprenorphine/naloxone)
- Discontinuation of opioids with oral clonidine and other symptomatic medications
Step therapy / utilization management not described
No step therapy or utilization management rules for anesthesia‑assisted opioid antagonist treatment are described in the provided policy excerpts.
- The document does not define prior medication trials or step requirements that must be completed before offering ultra‑rapid withdrawal.
Program structure and required documentation
Specialized programs offering ultra‑rapid withdrawal typically include three phases—comprehensive evaluation, inpatient withdrawal management under anesthesia (or outpatient if heavy sedation is used), and mandatory postwithdrawal care and follow‑up.
- Comprehensive evaluation to determine program eligibility.
- Inpatient withdrawal management when general anesthesia is used; outpatient possible with heavy sedation.
- Mandatory postwithdrawal management care and follow‑up, often including continuation of naltrexone.
Documentation requirements absent in excerpts
The provided excerpts do not specify required documentation elements or templates that providers must submit for authorization or claims related to anesthesia‑assisted opioid antagonist treatments.
- While the policy notes program phases and that hospitalization is required if general anesthesia is used, it does not list explicit documentation requirements.
Investigational treatment — potential denial
Anesthesia‑assisted or ultra‑rapid withdrawal using opioid antagonists is considered investigational; services may be denied on that basis.
- Policy states the approach is investigational due to insufficient evidence and documented significant adverse events.
- Denial risk applies because the procedure is considered not medically necessary/investigational.
Authorization/denial criteria not explicitly present
The excerpts do not provide explicit authorization or denial criteria beyond the investigational stance; providers should rely on member benefit plan language and the policy's investigational designation when anticipating coverage decisions.
- No step‑by‑step authorization criteria are listed in the provided text.
- The policy's investigational classification is the primary basis for noncoverage.
Clinical Background and Scope
Ultra-rapid (also described as anesthesia-assisted or one-day) withdrawal uses high-dose opioid antagonists administered under deep sedation or general anesthesia to precipitate and accelerate acute opioid withdrawal, often completed within 24–48 hours. Because patients are sedated, acute withdrawal is not experienced or recalled, and programs typically aim to transition patients to naltrexone and provide postwithdrawal psychosocial support. Evidence is limited and approaches are not standardized; significant adverse events, including life-threatening complications, have been reported. Programs are offered by specialized facilities and, if general anesthesia is used, usually require inpatient hospitalization with documented evaluation, management under anesthesia, and mandatory postwithdrawal follow-up.
Key Terms
Site of Care Considerations
Treatment Approaches and Medication Pathways
Anesthesia-assisted ultra-rapid withdrawal / MAT transition to naltrexone
Programs typically include comprehensive evaluation, inpatient withdrawal management under anesthesia, and mandatory postwithdrawal follow-up; naltrexone may be continued after acute management to discourage relapse.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.